XTL Biopharmaceuticals
XTLB
5 hedge funds and large institutions have $579K invested in XTL Biopharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.02% more ownership
Funds ownership: 0% → 0.02% (+0.02%)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
36% less capital invested
Capital invested by funds: $907K → $579K (-$328K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$12.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$9.54K |
| 3 |
Morgan Stanley
New York
|
+$607 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$20.6K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $434K | -$20.6K | -1,357 | -4% |
|
2
Invesco
Atlanta,
Georgia
| $82K | – | – | – |
|
|
3
Citadel Advisors
Miami,
Florida
| $50K | +$9.54K | +629 | +18% |
|
|
4
UBS Group
Zurich,
Switzerland
| $11K | +$12.9K | +847 | New |
|
|
5
Morgan Stanley
New York
| $2K | +$607 | +40 | +31% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| – | -$1K | -30 | Closed |
|
XTLB Hedge Fund Activity: Q4 2016 in Review
5 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2016, worth a combined $579K — down 36% from $907K a quarter earlier.
Fund positioning in XTLB was balanced in Q4 2016: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $12.9K. The largest seller was Sabby Management, cutting an estimated $20.6K.
- 5 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $579K of XTL Biopharmaceuticals stock for Q4 2016, down 36% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q4 2016 and 1 closed out, a net change of 0 holders.
- The largest XTL Biopharmaceuticals buyer in Q4 2016 was UBS Group, an estimated $12.9K added.
- The largest XTL Biopharmaceuticals seller in Q4 2016 was Sabby Management, an estimated $20.6K sold.
Based on aggregated 13F filings for Q4 2016.